- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01051739
Variability in Perimetry Study (VIPII)
Improved Assessment of Visual Field Change
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Disease of the optic nerve, including glaucoma, is the leading cause of blindness in the United States. Treatment decisions for optic nerve diseases are based largely on the changes in visual function that occur mostly as a consequence of disease progression. Unfortunately, the decision as to whether change of visual function has occurred is often difficult because of the high retest variability of conventional visual field testing (perimetry). This variability is so high that with moderate visual loss, a minimum of six tests are often needed in patients with optic nerve damage to reliably distinguish visual field deterioration from random variation. The preliminary data show that a substantial portion of the variability of perimetry lies in the type of stimulus used and the testing strategy applied.
OBJECTIVES: The investigators propose to test the hypothesis that a large portion of total perimetric variability in patients with visual loss is due to a poor signal-to-noise ratio associated with using a small fixed-size stimulus.
RESEARCH PLAN AND METHODS: To test this hypothesis, the investigators are examining patients with optic nerve diseases with conventional automated perimetry (size III) and tests having large-sized and scaled stimuli (size V, size VI (custom perimeter) and luminance size threshold perimetry - a test where threshold is found by changing stimulus size rather than stimulus intensity). Over four years the investigators will test 100 patients with and glaucoma and 60 normals each eight times. In addition, the investigators are retesting 50 subjects once a week for 5 weeks. The investigators are also studying the associated structural-functional correlations using OCT and developing a statistical model that accounts for correlations of neighboring test locations.
Perimetric variability and the reliable identification of visual field change is the single most difficult problem in visual testing today. The investigators anticipate identifying a method that allows efficient and accurate determination of visual field change. Identification of a superior method would (1) reduce the number of examinations needed, thereby reducing the costs of medical care; (2) minimize misdiagnosis, unnecessary testing and even unnecessary surgery that results from mistakenly interpreting fluctuation of the visual field as progression or improvement; (3) allow earlier disease intervention and (4) reduce the costs of clinical trials.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Iowa
-
Iowa City, Iowa, Förenta staterna, 52246-2208
- Iowa City VA Health Care System, Iowa City, IA
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Mean deviation of -20 or better with 5-8 points (optimally 10 points) with a value of p= 0.05 or better on the total deviation plot
- Mild cataract with VA of 20/30 or better pinholed
- Refractive error of = to or less than 6 diopters with = or less than 3.50 diopters of cylinder
- Pupil diameter of 3 mm minimum
- Controlled hypertension, diabetes, migraine
- Pseudophakic/refractive surgery if no vision problems
- Trabeculectomy okay
Exclusion Criteria:
- History of other ocular or neurologic disease or surgery
- History of stroke
- Systemic disease [lupus, graves, cancer (within the last 5 yrs), AIDS, other]
- History of amblyopia
- Unreliable patient
- Frequently misses appointments
- Tests poorly
- Ocular hypertension
- Retinal problems
- Diabetic retinopathy
- Neurological disease (IIH, ON, AION)
- Cancer not in remission for the last 5 years
- Vein or artery occlusions
- Macular degeneration
- Trauma with vision loss
- Ocular inflammation (pars planitis, iritis, temporal aeuritis)
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Case-Control
- Tidsperspektiv: Blivande
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Group 1
glaucoma
|
We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
|
Grupp 2
vanligt
|
We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Subjects Progressing in Each Group Using Pointwise Linear Regression
Tidsram: 4 years
|
Perimetric method that most efficiently detects visual field change.
secondary outcome: number of subjects progressing in each group using pointwise linear regression Linear regression was used to determine visual field worsening (progression) at each of 52 test locations.
We required 3 or more worsening test locations at a p = 0.05 significance level for their to be significant progression.
|
4 years
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Michael Wall, MD, Iowa City VA Health Care System, Iowa City, IA
Publikationer och användbara länkar
Allmänna publikationer
- Wall M, Doyle CK, Eden T, Zamba KD, Johnson CA. Size threshold perimetry performs as well as conventional automated perimetry with stimulus sizes III, V, and VI for glaucomatous loss. Invest Ophthalmol Vis Sci. 2013 Jun 7;54(6):3975-83. doi: 10.1167/iovs.12-11300.
- Kummet CM, Zamba KD, Doyle CK, Johnson CA, Wall M. Refinement of pointwise linear regression criteria for determining glaucoma progression. Invest Ophthalmol Vis Sci. 2013 Sep 19;54(9):6234-41. doi: 10.1167/iovs.13-11680.
- Wall M, Doyle CK, Zamba KD, Artes P, Johnson CA. The repeatability of mean defect with size III and size V standard automated perimetry. Invest Ophthalmol Vis Sci. 2013 Feb 15;54(2):1345-51. doi: 10.1167/iovs.12-10299.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- C7098-R
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .